Outlook Therapeutics (OTLK) Director Randy Thurman Buys 5,000 Shares

What Happened Randy H. Thurman, a director of Outlook Therapeutics, acquired 5,000 common shares on 2026-05-26. The reported purchase price was $0.43 per share for a total transaction value of $2,145. This was a purchase (reported with code "P"), which investors often pay attention to as insider buying can be more informative than routine selling.

Key Details

• Transaction date and price: 2026-05-26, 5,000 shares at $0.43 each (total $2,145).
• Transaction type: P — open market or private purchase (filing lists "P").
• Shares owned after transaction: Not specified in the provided filing details.
• Footnotes/plans: No 10b5-1 plan, tax withholding, or other footnotes were provided in the data supplied.
• Filing timeliness: Report filed 2026-05-27 for a 2026-05-26 transaction (filed within the normal 2-business-day Form 4 window).

Context The purchase amount is relatively small ($2,145), so while it is a director buy, the size limits the weight of any inference. No options, awards, gifts, or cashless sales were involved in this filing — it was a straightforward purchase as reported.